dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:23:58Z
dc.date.available2014-05-27T11:23:58Z
dc.date.created2014-05-27T11:23:58Z
dc.date.issued2009-09-15
dc.identifierJournal of Immune Based Therapies and Vaccines, v. 7, p. 4-.
dc.identifier1476-8518
dc.identifierhttp://hdl.handle.net/11449/71151
dc.identifier10.1186/1476-8518-7-4
dc.identifier2-s2.0-70449432883
dc.identifier2-s2.0-70449432883.pdf
dc.description.abstractBackground: Our group previously demonstrated that a DNA plasmid encoding the mycobacterial 65-kDa heat shock protein (DNA-HSP65) displayed prophylactic and therapeutic effect in a mice model for tuberculosis. This protection was attributed to induction of a strong cellular immunity against HSP65. As specific immunity to HSP60 family has been detected in arthritis, multiple sclerosis and diabetes, the vaccination procedure with DNA-HSP65 could induce a cross-reactive immune response that could trigger or worsen these autoimmune diseases. Methods: In this investigation was evaluated the effect of a previous vaccination with DNA-HSP65 on diabetes development induced by Streptozotocin (STZ). C57BL/6 mice received three vaccine doses or the corresponding empty vector and were then injected with multiple low doses of STZ. Results: DNA-HSP65 vaccination protected mice from STZ induced insulitis and this was associated with higher production of IL-10 in spleen and also in the islets. This protective effect was also concomitant with the appearance of a regulatory cell population in the spleen and a decreased infiltration of the islets by T CD8+ lymphocytes. The vector (DNAv) also determined immunomodulation but its protective effect against insulitis was very discrete. Conclusion: The data presented in this study encourages a further investigation in the regulatory potential of the DNA-HSP65 construct. Our findings have important implications for the development of new immune therapy strategies to combat autoimmune diseases. © 2009 Santos et al; licensee BioMed Central Ltd.
dc.languageeng
dc.relationJournal of Immune Based Therapies and Vaccines
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectCD103 antigen
dc.subjectCD4 antigen
dc.subjectCD8 antigen
dc.subjectcytotoxic T lymphocyte antigen 4
dc.subjectDNA vaccine
dc.subjectheat shock protein 65
dc.subjectinterleukin 10
dc.subjectinterleukin 2 receptor alpha
dc.subjectmonoclonal antibody
dc.subjectstreptozocin
dc.subjecttumor necrosis factor alpha
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectautoimmunity
dc.subjectCD8+ T lymphocyte
dc.subjectcontrolled study
dc.subjectcytokine production
dc.subjectDNA vector
dc.subjectimmunomodulation
dc.subjectimmunotherapy
dc.subjectinsulitis
dc.subjectlymphocyte subpopulation
dc.subjectlymphocytic infiltration
dc.subjectmale
dc.subjectmouse
dc.subjectMycobacterium
dc.subjectnonhuman
dc.subjectpancreas islet
dc.subjectregulatory T lymphocyte
dc.subjectspleen
dc.subjectstreptozocin diabetes
dc.subjecttreatment outcome
dc.titleDNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución